Radiopharm Theranostics Limited (RADX) News
Track canonical SquawkNews coverage tagged to RADX, Radiopharm Theranostics Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
RADX doses first patient in second Phase 1/2a BetaBart cohort
Radiopharm Theranostics (RADX) dosed the first patient in the second cohort of its Phase 1/2a trial of BetaBart (RV-01) in B7-H3 expressing solid tumors.
EQUITY | Aug 26, 2026, 11:00 AM UTC
M
Radiopharm Theranostics gets positive DSMC recommendation for 177Lu-RAD202 trial
Radiopharm Theranostics says its Data Safety and Monitoring Committee issued a positive recommendation to advance to Cohort 4 in the Phase 1 HEAT clinical trial of 177Lu-RAD202.
EQUITY | Aug 20, 2026, 11:00 AM UTC
H
RADX to meet U.S. FDA on RAD 101 Phase 3 trial design
Radiopharm Theranostics (RADX) says it will meet with the U.S. FDA to align on pivotal Phase 3 trial design for RAD 101 in the diagnosis of brain metastases.
REGULATION | Aug 17, 2026, 11:30 AM UTC
M
RADX Reports Business Update
RADX releases business update
EQUITY | Jul 31, 2026, 11:00 AM UTC
H
US Stocks Mixed; American Express Shares Fall Following Q2 Results
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 0.2% on Friday. Following the market opening Friday, the Dow traded up 0.17% to 51,799.17 while the NASDAQ declined 0.15% to 25,099.23. The S
MACRO | Jul 24, 2026, 01:45 PM UTC